PO-0728: BRCA2 mutation predicts poor survival in prostate cancer: A compelling evidence from 8,988 patientsCD133 has been commonly used as a cancer stem cell (CSC) marker in breast cancer. However, the correlation between CD133 expression, and clinicopathological characteristics and prognosis in ...
Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer withBRCA1andBRCA2founder mutations. Clin Cancer Res. 2009;15:1112–20.
Impact of germline DNA repair gene variants on prognosis and treatment of men with advanced prostate cancer Article Open access 06 November 2023 Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA...
Current treatment modalities for incident cases do not differ for age- and stage-matched sporadic breast cancer cases; although clinical trials with PARP inhibitors are currently underway. ▪ The prognosis for BRCA2-associated breast cancers has not been clearly established Read more View chapterExplo...
This article reviews the clinicopathological features, treatment, and prognosis of ER-positive and BRCA2-mutated BC to provide a reference for clinical decision-making.Introduction The most prevalent malignancy and the main reason for cancer-related mortality in women globally is BC [1]. It has ...
Methods for the Diagnosis, Prognosis and Monitoring of Cancer Therapy Using BP1 The invention described herein relates to method for diagnosing or monitoring the progression of a cancer, e.g., breast cancer, prostate cancer or brain cancer, in a subject by determining the amount of one or more...
Neuroendocrine prostate cancer (NEPC) is a highly aggressive histologic subtype of prostate cancer associated with a poor prognosis. Its incidence is expected to increase as castration-resistant disease emerges from the widespread use of potent androgen receptor-targeting therapies, such as abiraterone and...
Effects of BRCA1⁃and BRCA2⁃related mutations on ovarian and breast cancer survival: a meta⁃analysis[J]. Clin Cancer Res, 2015, 21(1): 211⁃220. DOI:10.1158/1078⁃0432.CCR⁃14⁃1816. [32] Goodwin PJ, Phillips KA, West DW, et al. Breast cancer prognosis in BRCA1 and ...
R. et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 97, 527–536 (2003). CAS PubMed Google Scholar Moller, P. et al. Survival in prospectively ascertained familial breast ...
Several features previously associated with poor PCa outcome have been found to be significantly more common in BRCA2-mutated PCa than in sporadic tumours and may help to explain their adverse prognosis and be of relevance for targeted therapies....